Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases
COVID-19 trials have relied on symptomatic subjects for judging the effectiveness of vaccine candidates, whereas asy–mptomatic subjects have been suspected as the main driver of the pandemic. An assumption of the same impact on symptomatic and asymptomatic breakthrough infections is shown to be flaw...
Main Author: | Richard Paul Junghans |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-12-01
|
Series: | Human Vaccines & Immunotherapeutics |
Online Access: | http://dx.doi.org/10.1080/21645515.2021.1994800 |
Similar Items
-
Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
by: Nick K Jones, et al.
Published: (2021-04-01) -
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
by: Rieke Reiter, et al.
Published: (2022-05-01) -
Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01) -
Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data
by: Frank van den Ouweland, et al.
Published: (2024-12-01) -
Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
by: Xin Rong Lim, et al.
Published: (2021-08-01)